Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications
- PMID: 28487100
- DOI: 10.1016/j.juro.2017.04.102
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications
Abstract
Purpose: PD-L1 is expressed on tumor cells and tumor immune cell infiltrates. In metastatic bladder cancer increased tumor immune cell infiltrate PD-L1 positivity correlated with better overall survival. However, to our knowledge in high grade T1 bladder tumors positivity on tumor cells and tumor immune cell infiltrates, and correlation with outcomes or pathological features remain unknown.
Materials and methods: Formalin fixed, paraffin embedded tumor samples from 140 patients with clinically annotated, high grade T1 bladder tumors were retrieved. All patients were initially diagnosed with high grade T1 bladder tumors by transurethral resection, subsequently received bacillus Calmette-Guérin and had a median followup of 7.4 years. PD-L1 positivity on initial transurethral resection was evaluated by immunohistochemistry using a mouse monoclonal antiPD-L1 antibody (405.9A11). Tumor cell PD-L1 positivity was defined as staining of 5% of the tumor cell membrane. Tumor immune cell infiltrate PD-L1 positivity was scored based on the extent of infiltrate and the percent of positive cells. The Fisher exact test was used to assess associations of PD-L1 positivity with disease outcomes, carcinoma in situ presence and the difference between high grade T1 bladder tumors and muscle invasive bladder cancer.
Results: Among 140 patients with high grade T1 bladder tumors tumor cells and tumor immune cell infiltrate PD-L1 positivity was seen in 6 (4%) and 48 (34.3%), respectively. In a subset of 106 patients with adequate followup PD-L1 positivity did not correlate with disease outcomes on tumor cells (p = 0.3) or on tumor immune cell infiltrates (p = 0.47). PD-L1 positivity also did not correlate with the presence of carcinoma in situ. Tumor cell PD-L1 positivity was significantly less in high grade T1 bladder tumors than in muscle invasive bladder cancer (p <0.001).
Conclusions: PD-L1 is widely expressed on tumor immune cell infiltrates but not on tumor cells in high grade T1 bladder tumors. We did not find a correlation between PD-L1 positivity and outcomes or carcinoma in situ presence. Tumor cell PD-L1 positivity is significantly lower in high grade T1 bladder tumors than in muscle invasive bladder cancer.
Keywords: CD274 protein; bladder neoplasms; human; neoplasm grading; neoplasm invasiveness; urothelium.
Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Re: Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications: S. A. M. Wankowicz, L. Werner, A. Orsola, J. Novak, M. Bowden, T. K. Choueiri, I. de Torres, J. Morote, G. J. Freeman, S. Signoretti and J. Bellmunt J Urol 2017;198:817-823.J Urol. 2018 Mar;199(3):854-856. doi: 10.1016/j.juro.2017.09.145. Epub 2017 Nov 24. J Urol. 2018. PMID: 29179001 No abstract available.
Similar articles
-
High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.Future Oncol. 2021 Aug;17(22):2893-2905. doi: 10.2217/fon-2021-0092. Epub 2021 Jun 30. Future Oncol. 2021. PMID: 34189951
-
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.Cancer. 2007 Apr 15;109(8):1499-505. doi: 10.1002/cncr.22588. Cancer. 2007. PMID: 17340590
-
PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.Hum Pathol. 2018 Nov;81:184-191. doi: 10.1016/j.humpath.2018.06.028. Epub 2018 Jun 30. Hum Pathol. 2018. PMID: 29969606
-
Management of high-risk non-muscle invasive bladder cancer.Minerva Urol Nefrol. 2012 Dec;64(4):255-60. Minerva Urol Nefrol. 2012. PMID: 23288212 Review.
-
ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.World J Urol. 2019 Jan;37(1):51-60. doi: 10.1007/s00345-018-2438-9. Epub 2018 Aug 14. World J Urol. 2019. PMID: 30109483 Review.
Cited by
-
COL6A1 expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype.Investig Clin Urol. 2024 Jan;65(1):94-103. doi: 10.4111/icu.20230227. Investig Clin Urol. 2024. PMID: 38197756 Free PMC article.
-
Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 Expression.Cancers (Basel). 2022 Dec 28;15(1):188. doi: 10.3390/cancers15010188. Cancers (Basel). 2022. PMID: 36612181 Free PMC article.
-
Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.J Clin Med. 2024 Apr 10;13(8):2182. doi: 10.3390/jcm13082182. J Clin Med. 2024. PMID: 38673455 Free PMC article. Review.
-
Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.World J Urol. 2020 Oct;38(10):2537-2545. doi: 10.1007/s00345-019-03065-2. Epub 2020 Jan 3. World J Urol. 2020. PMID: 31900581
-
Bacillus Calmette-Guérin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer.Front Oncol. 2022 Mar 3;12:842182. doi: 10.3389/fonc.2022.842182. eCollection 2022. Front Oncol. 2022. PMID: 35311085 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials